PharmTech Drug Digest 11.20
News|Articles|October 7, 2013

Waters Introduces Mass Detector for Chromatography Separations

The Waters ACQUITY QDa Detector is a mass detector designed to bring high-quality, mass spectral data to chromatographic separations.

The Waters ACQUITY QDa Detector is a mass detector designed to bring high-quality, mass spectral data to chromatographic separations. The detector, introduced on Oct. 7 by Waters Corp., is now shipping worldwide.

Designed as a component of a chromatographic system, the ACQUITY QDa Detector is compatible with Waters ACQUITY UltraPerformance LC, ACQUITY UltraPerformance Convergence Chromatography, Alliance high performance liquid chromatography and Waters supercritical fluid chromatography and LC-based purification systems.

The system is designed for analytical scientists who need mass spectral data without the complexity of a mass spectrometer. It features automated sample analysis and eliminates sample-specific adjustments for certainty in sample results, from user to user and system to system. The detector generates the high quality mass spectral data expected of a single quadrupole mass spectrometer in a mass detector no bigger than a photodiode array (PDA) detector.

The ACQUITY QDa Detector complements optical detection, such as the PDA detector, by confirming the identity of compounds with mass spectral information; quantifies compounds having no UV response or that are present at levels not detectable and quantifiable by optical detection, the company reports.

The ACQUITY QDa Detector is available for separations systems running Empower 2 and 3 Chromatography Data System software, including enterprise deployment with automated qualification. The ACQUITY QDa Detector is also available now for MassLynx 4.1 Mass Spectrometry Software.

Source: Waters Corp.

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.